Stocks · News reference
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition
Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expected to close in Q4 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Assumes Revvity at Neutral, Raises Price Target to $140
Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And Preclinical Research Solutions For Diabetes, Obesity And Other Metabolic Diseases
The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including applications in GLP-1 and other